|
CH652145A5
(de)
|
1982-01-22 |
1985-10-31 |
Sandoz Ag |
Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
|
|
US4634666A
(en)
|
1984-01-06 |
1987-01-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Human-murine hybridoma fusion partner
|
|
US5208036A
(en)
|
1985-01-07 |
1993-05-04 |
Syntex (U.S.A.) Inc. |
N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
EP0832981A1
(en)
|
1987-02-17 |
1998-04-01 |
Pharming B.V. |
DNA sequences to target proteins to the mammary gland for efficient secretion
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US4912094B1
(en)
|
1988-06-29 |
1994-02-15 |
Ribi Immunochem Research Inc. |
Modified lipopolysaccharides and process of preparation
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5633076A
(en)
|
1989-12-01 |
1997-05-27 |
Pharming Bv |
Method of producing a transgenic bovine or transgenic bovine embryo
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
DK0585287T3
(da)
|
1990-07-10 |
2000-04-17 |
Cambridge Antibody Tech |
Fremgangsmåde til fremstilling af specifikke bindingsparelementer
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5194594A
(en)
|
1990-09-07 |
1993-03-16 |
Techniclone, Inc. |
Modified antibodies
|
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Technology Ltd. |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5674703A
(en)
|
1992-12-02 |
1997-10-07 |
Woo; Savio L. C. |
Episomal vector systems and related methods
|
|
ES2156149T3
(es)
|
1992-12-04 |
2001-06-16 |
Medical Res Council |
Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
|
|
WO1994013795A1
(en)
|
1992-12-14 |
1994-06-23 |
N.V. Innogenetics S.A. |
Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
|
|
DE69435171D1
(de)
|
1993-09-14 |
2009-01-08 |
Pharmexa Inc |
Pan dr-bindeproteinen zur erhöhung der immunantwort
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5914349A
(en)
|
1994-01-10 |
1999-06-22 |
Teva Pharmaceutical Industries, Ltd. |
Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
|
|
US5505947A
(en)
|
1994-05-27 |
1996-04-09 |
The University Of North Carolina At Chapel Hill |
Attenuating mutations in Venezuelan Equine Encephalitis virus
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
US7427392B1
(en)
|
1994-11-14 |
2008-09-23 |
Elan Pharmaceuticals, Inc. |
Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
DE19539493A1
(de)
|
1995-10-24 |
1997-04-30 |
Thomae Gmbh Dr K |
Starker homologer Promotor aus Hamster
|
|
US5834597A
(en)
|
1996-05-20 |
1998-11-10 |
Protein Design Labs, Inc. |
Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
FR2755144B1
(fr)
*
|
1996-10-29 |
1998-11-27 |
Rhone Poulenc Rorer Sa |
Fragments d'anticorps a chaine unique anti-p53 et utilisation
|
|
AUPO390396A0
(en)
|
1996-11-29 |
1996-12-19 |
Csl Limited |
Novel promiscuous T helper cell epitopes
|
|
DK1005368T3
(da)
|
1997-03-10 |
2010-01-04 |
Ottawa Hospital Res Inst |
Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
|
|
US5888809A
(en)
|
1997-05-01 |
1999-03-30 |
Icos Corporation |
Hamster EF-1α transcriptional regulatory DNA
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
NZ513144A
(en)
|
1999-02-05 |
2003-05-30 |
Samsung Electronics Co Ltd |
Image texture retrieving method and apparatus thereof
|
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
|
AT500379B8
(de)
|
2001-02-02 |
2009-08-15 |
Axon Neuroscience |
Tau-proteine
|
|
MXPA05000511A
(es)
|
2001-07-12 |
2005-09-30 |
Jefferson Foote |
Anticuepros super humanizados.
|
|
EP1470146B8
(en)
|
2001-12-28 |
2007-09-12 |
Amgen Fremont Inc. |
Antibodies against the muc18 antigen
|
|
JP4393382B2
(ja)
|
2002-08-14 |
2010-01-06 |
三菱化学株式会社 |
中枢性タウ蛋白質特異的抗体
|
|
JP4344325B2
(ja)
|
2002-11-29 |
2009-10-14 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
|
|
US7847146B2
(en)
|
2003-03-28 |
2010-12-07 |
Baylor College Of Medicine |
Model for neurodegenerative disorders
|
|
DE10338531A1
(de)
|
2003-08-19 |
2005-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Reklonierung von Produktionszellen
|
|
US20050132424A1
(en)
|
2003-10-21 |
2005-06-16 |
Envivo Pharmaceuticals, Inc. |
Transgenic flies expressing Abeta42-Dutch
|
|
WO2006037604A1
(en)
|
2004-10-01 |
2006-04-13 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel antibodies directed to the mammalian eag1 ion channel protein
|
|
CA2578400C
(en)
|
2004-11-10 |
2014-01-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
|
|
CA2591665C
(en)
|
2004-12-20 |
2015-05-05 |
Crucell Holland B.V. |
Binding molecules capable of neutralizing west nile virus and uses thereof
|
|
EP1833850B9
(en)
|
2004-12-30 |
2011-05-18 |
The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services |
Framework residue substituted humanized col-1 antibodies and their use
|
|
US8012936B2
(en)
|
2006-03-29 |
2011-09-06 |
New York University |
Tau fragments for immunotherapy
|
|
EP2028932A4
(en)
|
2006-06-16 |
2011-10-12 |
Vitruvean Llc |
TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY
|
|
CA2655379A1
(en)
|
2006-06-22 |
2007-12-27 |
Walter And Eliza Hall Institute Of Medical Research |
Structure of the insulin receptor ectodomain
|
|
US20080124760A1
(en)
|
2006-07-26 |
2008-05-29 |
Barbara Enenkel |
Regulatory Nucleic Acid Elements
|
|
US20100216703A1
(en)
|
2006-08-14 |
2010-08-26 |
The Regents Of The University Of California |
Inhibitors of PDE4 and Methods of Use
|
|
US8481683B2
(en)
|
2006-12-01 |
2013-07-09 |
Medarex, Inc. |
Human antibodies that bind CD22 and uses thereof
|
|
PT2099823E
(pt)
|
2006-12-01 |
2014-12-22 |
Seattle Genetics Inc |
Agentes de ligação ao alvo variantes e suas utilizações
|
|
GB0624500D0
(en)
*
|
2006-12-07 |
2007-01-17 |
Istituto Superiore Di Sanito |
A novel passive vaccine for candida infections
|
|
WO2008081008A1
(en)
|
2007-01-05 |
2008-07-10 |
University Of Zurich |
Method of providing disease-specific binding molecules and targets
|
|
PL2583978T3
(pl)
|
2007-02-23 |
2016-07-29 |
Prothena Biosciences Ltd Co |
Profilaktyka i leczenie chorób synukleinopatycznych i amyloidogennych
|
|
NZ580043A
(en)
|
2007-03-02 |
2012-04-27 |
Boehringer Ingelheim Pharma |
Improvement of protein production through increased expression of mutated start domain protein cert
|
|
EP2031064A1
(de)
|
2007-08-29 |
2009-03-04 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Verfahren zur Steigerung von Proteintitern
|
|
JP2009056790A
(ja)
|
2007-09-03 |
2009-03-19 |
Takao Otogawa |
ファイル用ポケット
|
|
EP2497783A3
(en)
|
2007-09-26 |
2013-04-17 |
U3 Pharma GmbH |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
|
UA104132C2
(en)
|
2007-11-13 |
2014-01-10 |
Тева Биофармасьютикалз Юесей, Инк. |
Humanized antibodies against tl1a
|
|
JP2010014691A
(ja)
|
2008-06-20 |
2010-01-21 |
Igaku Seibutsugaku Kenkyusho:Kk |
腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
|
|
RU2547595C2
(ru)
|
2008-08-18 |
2015-04-10 |
Пфайзер Инк |
Антитела против ccr2
|
|
US9605054B2
(en)
|
2009-02-23 |
2017-03-28 |
The Board Of Trustees Of The University Of Illinois |
Composition and method for treating a tauopathy
|
|
NZ621170A
(en)
|
2009-05-13 |
2015-08-28 |
Genzyme Corp |
Anti-human cd52 immunoglobulins
|
|
CN106390107B
(zh)
|
2009-06-10 |
2019-12-31 |
纽约大学 |
病理tau蛋白的免疫靶向
|
|
US20110045534A1
(en)
|
2009-08-20 |
2011-02-24 |
Cell Signaling Technology, Inc. |
Nucleic Acid Cassette For Producing Recombinant Antibodies
|
|
AU2010286501B2
(en)
|
2009-08-28 |
2015-06-11 |
The Board Of Regents Of The University Of Texas System |
Antibodies that bind Tau oligomers
|
|
WO2011053565A2
(en)
|
2009-10-29 |
2011-05-05 |
Biomedical Sciences Research Centre "Alexander Fleming" |
Compositions and methods for detecting a tauopathy
|
|
US20120288507A1
(en)
|
2009-12-18 |
2012-11-15 |
Amgen Inc. |
Wise binding agents and epitopes
|
|
US8945576B2
(en)
*
|
2010-01-08 |
2015-02-03 |
Kyoto University |
Vaccine for treatment of tautopathy
|
|
MA34057B1
(fr)
|
2010-02-23 |
2013-03-05 |
Genentech Inc |
Compositions et methodes pour le diagnostic et le traitement d'une tumeur
|
|
US8987419B2
(en)
|
2010-04-15 |
2015-03-24 |
AbbVie Deutschland GmbH & Co. KG |
Amyloid-beta binding proteins
|
|
EP2560681A4
(en)
*
|
2010-04-22 |
2013-09-25 |
Janssen Alzheimer Immunotherap |
USE OF TAU FOR MONITORING IMMUNOTHERAPY
|
|
ITRM20100320A1
(it)
|
2010-06-11 |
2011-12-11 |
Consiglio Nazionale Ricerche |
Metodo per la diagnostica e il trattamento delle taupatie
|
|
US20120023911A1
(en)
|
2010-07-28 |
2012-02-02 |
Gm Global Technology Operations, Inc. |
Detection of exhaust particulate filter substrate failure
|
|
CA2813493C
(en)
|
2010-10-11 |
2019-07-09 |
University Of Zurich |
Human anti-tau antibodies
|
|
AU2011345312A1
(en)
*
|
2010-11-09 |
2013-06-20 |
Sarcotein Diagnostics Llc |
BIN1 expression as a marker of skeletal muscle mass and neurological conditions
|
|
JP2014511174A
(ja)
|
2011-02-07 |
2014-05-15 |
ネオトープ バイオサイエンシーズ リミテッド |
Ａｐｏｅ免疫療法
|
|
EP2701743A4
(en)
|
2011-04-27 |
2015-08-19 |
Univ Northwestern |
FOR PATHOLOGICAL TAU-DIMERE AND PREAFIBRILLARY PATHOLOGICAL TAU-OLIGOMER SELECTIVE ANTIBODIES AND THEIR USES IN THE APPLICATION, DIAGNOSIS AND MONITORING OF TAUOPATHIES
|
|
GB201109238D0
(en)
|
2011-06-01 |
2011-07-13 |
Antitope Ltd |
Antibodies
|
|
GB201111361D0
(en)
|
2011-07-04 |
2011-08-17 |
Nordic Bioscience As |
Biochemical markers for neurodegenerative conditions
|
|
GB201112056D0
(en)
|
2011-07-14 |
2011-08-31 |
Univ Leuven Kath |
Antibodies
|
|
SG11201400916XA
(en)
|
2011-08-22 |
2014-06-27 |
Cangene Corp |
Clostridium difficile antibodies
|
|
ME03008B
(me)
*
|
2011-09-19 |
2018-10-20 |
Axon Neuroscience Se |
Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
|
|
TWI573590B
(zh)
|
2011-09-20 |
2017-03-11 |
雷希爾生藥有限公司 |
治療自體免疫疾病之組成物及方法
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
KR101981351B1
(ko)
*
|
2011-10-07 |
2019-09-02 |
에이씨 이뮨 에스.에이. |
타우를 인식하는 포스포특이적 항체
|
|
HUE037720T2
(hu)
|
2012-03-28 |
2018-09-28 |
Sanofi Sa |
Bradikinin B1 receptor ligandumok elleni antitestek
|
|
RU2644242C2
(ru)
|
2012-04-05 |
2018-02-08 |
Ац Иммуне С.А. |
Гуманизированное тау-антитело
|
|
US9428864B2
(en)
|
2012-04-18 |
2016-08-30 |
E I Du Pont De Nemours And Company |
Multilayered sheet
|
|
SG10201708959WA
(en)
|
2012-07-03 |
2017-11-29 |
Univ Washington |
Antibodies to tau
|
|
NZ630542A
(en)
|
2012-08-16 |
2017-06-30 |
Ipierian Inc |
Methods of treating a tauopathy
|
|
US20140056901A1
(en)
*
|
2012-08-21 |
2014-02-27 |
The Institute For Molecular Medicine |
Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
|
|
EP2906596B1
(en)
*
|
2012-10-12 |
2023-12-27 |
Arizona Board of Regents on behalf of Arizona State University |
Antibody based reagents that specifically recognize toxic oligomeric forms of tau
|
|
US9200068B2
(en)
|
2012-12-18 |
2015-12-01 |
Regents Of The University Of Minnesota |
Compositions and methods related to tauopathy
|
|
CA2896066C
(en)
*
|
2012-12-21 |
2022-07-12 |
Biogen Ma Inc. |
Human anti-tau antibodies
|
|
US8980270B2
(en)
|
2013-01-18 |
2015-03-17 |
Ipierian, Inc. |
Methods of treating a tauopathy
|
|
US9364191B2
(en)
|
2013-02-11 |
2016-06-14 |
University Of Rochester |
Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT
|
|
US10501531B2
(en)
|
2013-03-13 |
2019-12-10 |
Prothena Biosciences Limited |
Tau immunotherapy
|
|
CA2939692C
(en)
*
|
2013-03-15 |
2022-10-18 |
The Trustees Of The University Of Pennsylvania |
Blood biomarkers that predict persistent cognitive dysfunction after concussion
|
|
EP2968548B1
(en)
|
2013-03-15 |
2020-09-09 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for the generation and use of conformation-specific antibodies
|
|
HK1225740A1
(zh)
|
2013-08-22 |
2017-09-15 |
Acceleron Pharma Inc. |
TGF-β受体II型变体及其用途
|
|
BR112016010454A2
(pt)
|
2013-11-27 |
2017-12-05 |
Ipierian Inc |
métodos para tratar uma taupatia
|
|
WO2015089375A1
(en)
|
2013-12-13 |
2015-06-18 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
|
IL263466B2
(en)
|
2013-12-17 |
2023-10-01 |
Genentech Inc |
Anti-CD3 antibodies and methods of using them
|
|
US9629801B2
(en)
*
|
2014-01-10 |
2017-04-25 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
|
US20150253341A1
(en)
|
2014-02-10 |
2015-09-10 |
Merck Sharp & Dohme Corp. |
Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry
|
|
BR112016029579A2
(pt)
|
2014-06-26 |
2017-08-22 |
Janssen Vaccines & Prevention Bv |
anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
|
|
TWI734975B
(zh)
|
2014-06-27 |
2021-08-01 |
美商Ｃ２Ｎ醫療診斷有限責任公司 |
人類化抗-tau抗體
|
|
CN107428820B
(zh)
*
|
2014-11-19 |
2022-03-22 |
阿克松神经系统科学公司 |
在阿尔茨海默氏病中的人源化tau抗体
|
|
CA2874083C
(en)
*
|
2014-12-05 |
2024-01-02 |
Universite Laval |
Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
|
|
EP3261670A4
(en)
|
2015-02-24 |
2018-08-01 |
Rpeptide, LLC |
Anti-tau antibodies
|
|
NZ775762A
(en)
|
2015-06-05 |
2025-02-28 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
US20200030445A1
(en)
|
2015-06-12 |
2020-01-30 |
C2N Diagnostics, Llc |
Stable formulations of humanized anti-tau antibody
|
|
US10344081B2
(en)
|
2015-07-06 |
2019-07-09 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
|
WO2017013599A1
(en)
|
2015-07-21 |
2017-01-26 |
Bioarctic Neuroscience Ab |
Method for treatment of traumatic brain injury targeting aggregated peptides
|
|
US20190330335A1
(en)
|
2015-10-06 |
2019-10-31 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
|
PT3452507T
(pt)
|
2016-05-02 |
2022-12-20 |
Prothena Biosciences Ltd |
Imunoterapia anti-tau
|
|
MX2018013386A
(es)
|
2016-05-02 |
2019-02-28 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau.
|
|
MY198194A
(en)
*
|
2016-05-02 |
2023-08-09 |
Prothena Biosciences Ltd |
Antibodies Recognizing Tau
|
|
WO2018085653A1
(en)
|
2016-11-04 |
2018-05-11 |
The Regents Of The University Of California |
Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
|
|
MX2019006330A
(es)
|
2016-12-07 |
2019-09-26 |
Genentech Inc |
Anticuerpos anti-tau y metodos de uso.
|
|
UA128383C2
(uk)
|
2016-12-07 |
2024-07-03 |
Дженентек, Інк. |
Антитіло до тау-білка та спосіб його застосування
|
|
SG11201907422RA
(en)
|
2017-02-17 |
2019-09-27 |
Denali Therapeutics Inc |
Anti-tau antibodies and methods of use thereof
|
|
JP7165995B2
(ja)
|
2017-02-21 |
2022-11-07 |
アールイーエムディー バイオセラピューティクス，インコーポレイテッド |
細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
|
|
TWI771389B
(zh)
|
2017-03-16 |
2022-07-21 |
美商健生生物科技公司 |
抗phf-tau抗體及其用途
|
|
EP3601337A1
(en)
|
2017-03-28 |
2020-02-05 |
Genentech, Inc. |
Methods of treating neurodegenerative diseases
|
|
CA3056517A1
(en)
|
2017-03-28 |
2018-10-04 |
Janssen Vaccines & Prevention B.V. |
Binding molecules that specifically bind to tau
|
|
KR102784294B1
(ko)
|
2017-05-02 |
2025-03-19 |
프로테나 바이오사이언시즈 리미티드 |
타우 인식 항체
|
|
WO2018231254A1
(en)
|
2017-06-16 |
2018-12-20 |
Bristol-Myers Squibb Company |
Compositions and methods for treating tauopathies
|
|
AU2018352308B2
(en)
|
2017-10-16 |
2025-06-05 |
Eisai R&D Management Co., Ltd. |
Anti-tau antibodies and uses thereof
|
|
EP3706795A4
(en)
|
2017-11-09 |
2021-10-13 |
Pinteon Therapeutics Inc. |
METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
|
|
KR20200094177A
(ko)
|
2017-12-04 |
2020-08-06 |
얀센 백신스 앤드 프리벤션 비.브이. |
타우에 특이적으로 결합하는 결합 분자
|
|
WO2019180261A1
(en)
|
2018-03-23 |
2019-09-26 |
AbbVie Deutschland GmbH & Co. KG |
Stable aqueous anti-tau antibody formulations
|
|
SG11202008098TA
(en)
|
2018-03-28 |
2020-10-29 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
|
US20210230255A1
(en)
|
2018-04-27 |
2021-07-29 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
|
CA3118818A1
(en)
|
2018-11-08 |
2020-05-14 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
CU24781B1
(es)
|
2018-11-08 |
2026-02-09 |
Prothena Biosciences Ltd |
Anticuerpos humanizados que reconocen tau
|
|
EP3883602A4
(en)
|
2018-11-19 |
2023-04-12 |
The Board Of Regents Of The University Of Texas System |
TAU PEPTIDE ANTIGENS AND ANTIBODIES BINDING TO THEM FOR THE TREATMENT OF TAUOPATHIES
|
|
WO2020163817A1
(en)
|
2019-02-08 |
2020-08-13 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
|
JP7630834B2
(ja)
|
2019-03-03 |
2025-02-18 |
プロセナ バイオサイエンシーズ リミテッド |
タウ認識抗体
|
|
JP2022526334A
(ja)
|
2019-03-25 |
2022-05-24 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
新たなタウ種を標的化することによるタウオパチー障害の処置の方法
|
|
EP4001305A4
(en)
|
2019-07-15 |
2022-10-12 |
Adel Inc. |
ANTI-TAU ANTIBODIES AND ITS USE
|